Dataset from A Phase III/IV, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (TAIL)

This is a Phase III/IV, single-arm, multicenter study of the long-term safety and efficacy of
atezolizumab treatment in participants with Stage IIIb or Stage IV NSCLC who have progressed
after standard systemic chemotherapy (including if given in combination with anti-programmed
cell death protein 1 [anti-PD-1] therapy, after anti-PD-1 as monotherapy, or after tyrosine
kinase inhibitor [TKI] therapy). The study will consist of a Screening Period, a Treatment
Period, a Treatment Discontinuation Visit, and a Follow-Up Period.